Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
208
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

245
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
245
Glucose Transporters01:27

Glucose Transporters

23.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.0K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Istaroxime in Acute Heart Failure and Early Cardiogenic Shock: A Calcium-Cycling Approach to Inotropic Therapy.

International journal of molecular sciences·2026
Same author

Immunothrombotic Cell-Cell Communication Networks in Coronary Atherosclerosis: Critical Insights from Single-Cell and Spatial Systems Biology.

International journal of molecular sciences·2026
Same author

From Continuous-Flow Mechanical Circulatory Support to Heart Transplantation: Hemodynamic, Immunometabolic, and Body Composition Determinants of Rehabilitation Outcomes.

Journal of clinical medicine·2026
Same author

From Biomaterials to Biological State Engineering: Reframing Advanced Wound Dressings as Adaptive Therapeutic Interfaces in Translational Medicine.

Cells·2026
Same author

Vericiguat in the Post-Stabilization Phase of HFrEF: Targeting Residual Risk Across the Ischemia-Decompensation Continuum.

International journal of molecular sciences·2026
Same author

Beyond DSM Categories: Criteria for Biologically Valid Disease Axes in Psychiatry.

Journal of clinical medicine·2026

相关实验视频

Updated: Jul 21, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.6K

-葡萄糖共运输体2 抑制剂降低尿酸度-一种新的作用机制

Anna Kochanowska1, Przemysław Rusztyn1, Karolina Szczerkowska1

  • 11st Chair and Department of Cardiology, Medical University of Warsaw, 02-091 Warsaw, Poland.

Journal of cardiovascular development and disease
|July 28, 2023
PubMed
概括

-葡萄糖共运输体2抑制剂 (SGLT2is) 显著降低血清尿酸 (SUA) 水平. 这种可能与尿路尿酸分泌量增加相关的效应,可能解释了它们对心血管系统的一些益处.

关键词:
这就是SGLT2i.这就是Flozins.痛风是一种痛风.葡萄糖携带载体 2 抑制剂尿酸是什么 尿酸是什么

更多相关视频

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.6K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

相关实验视频

Last Updated: Jul 21, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.6K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.6K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

科学领域:

  • 心脏病学 心脏病学
  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 内分泌学 在内分泌学.

背景情况:

  • -葡萄糖共运输体2抑制剂 (SGLT2is) 是已确定的降血糖剂,具有显著的心血管益处.
  • 这些好处扩展到改善脂质样本,血压,动脉样硬化风险,以及减少心血管事件和死亡率.
  • 这些类作用的潜在机制包括SGLT2is对血清尿酸 (SUA) 度的影响.

研究的目的:

  • 综合了关于SGLT2is对SUA水平影响的元分析的发现.
  • 探索影响SGLT2i介导的SUA减少的因素.
  • 讨论SGLT2is对SUA调节在心血管疾病和痛风治疗中的潜在影响.

主要方法:

  • 现有研究的系统审查和元分析.
  • 对SGLT2i对SUA的影响药物和剂量依赖性的分析.
  • 调查影响因素,如HbA1c,糖尿病状况和基线SUA.

主要成果:

  • 九个元分析证实,SGLT2显著降低了SUA水平.
  • 关于药物和剂量依赖性的数据是不确定的.
  • 诸如HbA1c,糖尿病存在和基线SUA等因素影响SUA降低效应.

结论:

  • SGLT2明显降低了SUA,可能是通过尿尿酸分泌量增加.
  • 精确的机制需要进一步阐明.
  • 通过SGLT2is对SUA的调节可能有助于它们的心血管保护作用,并且在痛风中具有潜在的治疗应用.